GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Effective Interest Rate on Debt %

PARNF (Parnell Pharmaceuticals Holdings) Effective Interest Rate on Debt % : 17.63% (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Parnell Pharmaceuticals Holdings's annualized positive value of Interest Expense for the quarter that ended in Dec. 2018 was $5.01 Mil. Parnell Pharmaceuticals Holdings's average total debt for the quarter that ended in Dec. 2018 was $28.45 Mil. Therefore, Parnell Pharmaceuticals Holdings's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2018 was 17.63%.


Parnell Pharmaceuticals Holdings Effective Interest Rate on Debt % Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Effective Interest Rate on Debt % Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Effective Interest Rate on Debt %
Get a 7-Day Free Trial 58.90 11.16 16.23 30.38 17.63

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Effective Interest Rate on Debt % Get a 7-Day Free Trial 169.41 11.16 16.23 30.38 17.63

Competitive Comparison of Parnell Pharmaceuticals Holdings's Effective Interest Rate on Debt %

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's Effective Interest Rate on Debt % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's Effective Interest Rate on Debt % falls into.



Parnell Pharmaceuticals Holdings Effective Interest Rate on Debt % Calculation

Parnell Pharmaceuticals Holdings's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2018 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2017 )+Total Debt  (A: Dec. 2018 ))/ count )
=-1  *  -5.014/( (24.607+32.289)/ 2 )
=-1  *  -5.014/28.448
=17.63 %

where

Total Debt  (A: Dec. 2017 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=24.599 + 0.008
=24.607

Total Debt  (A: Dec. 2018 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=32.282 + 0.007
=32.289

Parnell Pharmaceuticals Holdings's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2018 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2017 )+Total Debt  (Q: Dec. 2018 ))/ count )
=-1  *  -5.014/( (24.607+32.289)/ 2 )
=-1  *  -5.014/28.448
=17.63 %

where

Total Debt  (Q: Dec. 2017 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=24.599 + 0.008
=24.607

Total Debt  (Q: Dec. 2018 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=32.282 + 0.007
=32.289

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is one times the annual (Dec. 2018) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Parnell Pharmaceuticals Holdings Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.